Insider Selling: Solazyme General Counsel Sells 8,500 Shares of Stock (SZYM)
Solazyme (NASDAQ:SZYM) General Counsel Paul T. Quinlan sold 8,500 shares of the stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $9.43, for a total transaction of $80,155.00. Following the sale, the general counsel now directly owns 86,875 shares in the company, valued at approximately $819,231. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Solazyme in a research note on Friday, May 30th. They now have a $15.00 price target on the stock. One analyst has rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Solazyme currently has a consensus rating of “Buy” and an average target price of $15.00.
Shares of Solazyme (NASDAQ:SZYM) opened at 9.17 on Friday. Solazyme has a 1-year low of $8.00 and a 1-year high of $15.00. The stock’s 50-day moving average is $9.82 and its 200-day moving average is $10.99. The company’s market cap is $721.7 million.
Solazyme (NASDAQ:SZYM) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.43) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.36) by $0.07. The company had revenue of $15.94 million for the quarter, compared to the consensus estimate of $17.13 million. During the same quarter last year, the company posted ($0.28) earnings per share. Solazyme’s revenue was up 42.6% compared to the same quarter last year. On average, analysts predict that Solazyme will post $-1.71 earnings per share for the current fiscal year.
Solazyme, Inc operates as a renewable oil production company. The Company fuels include microbial-derived jet fuels, bio-diesels, and renewable diesels.
Receive News & Ratings for Solazyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solazyme Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.